A phase II study of bortezomib in combination with rituximab, fludarabine, mitoxantrone, and dexamethasone (VR-FND) for relapsed or refractory follicular lymphoma.

Trial Profile

A phase II study of bortezomib in combination with rituximab, fludarabine, mitoxantrone, and dexamethasone (VR-FND) for relapsed or refractory follicular lymphoma.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 10 Jun 2014

At a glance

  • Drugs Bortezomib (Primary) ; Dexamethasone; Fludarabine; Mitoxantrone; Rituximab
  • Indications Follicular lymphoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 19 Apr 2014 Status changed from completed to discontinued as reported by ClinicalTrials.gov.
    • 01 Sep 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 17 Feb 2012 Planned End Date changed from 1 Jun 2013 to 1 Sep 2013 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top